The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis

Background: Melatonin (MLT) might benefit heart and metabolic health, as well as sleep quality, in individuals with chronic kidney disease (CKD), but the research findings are mixed. To better understand this, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess how MLT affects people with CKD.

Methods: Scopus, the Cochrane Library, PubMed, Web of Science, and Embase were searched up to May 30, 2025, for RCTs reporting lipid profiles, oxidative stress markers, or sleep quality. Random-effects meta-analyses were performed, and results are presented as weighted mean differences (WMDs) with 95% confidence intervals (CIs).

Results: Ten RCTs (12 trials) were included. MLT supplementation significantly increased high-density lipoprotein cholesterol (HDL-C: WMD = 1.87 mg/dL, 95% CI: 0.24, 3.50, p = 0.025; I² = 38.9, p = 0.179), and reduced malondialdehyde (MDA: −1.28 μmol/L, 95% CI: −2.50, −0.06, p = 0.039; I² = 93.4, p < 0.001), and improved sleep quality (PSQI: WMD = -3.75, 95% CI: −6.92, −0.57, p = 0.021; I² = 94.2, p < 0.001). Also, MLT supplementation had no significant effect on triglycerides, total cholesterol, low-density lipoprotein cholesterol, or C-reactive protein.

Conclusion: Supplementing with MLT in CKD can gently raise HDL-C levels, decrease oxidative stress, and improve sleep quality. While these effects are encouraging, more extensive and carefully planned clinical trials are necessary to verify the actual benefits.

Introduction

Chronic kidney disease (CKD) is a major global health issue, affecting roughly 10–15% of adults worldwide (1). Its incidence is rising due to aging populations and the growing prevalence of diabetes, hypertension, and obesity (2). CKD causes a gradual decline in kidney function and carries a much higher risk of cardiovascular disease (CVD). In fact, CVD is the leading cause of illness and death in CKD patients.

Key factors that raise cardiovascular risk and promote CKD progression are dyslipidemia, persistent inflammation, and oxidative stress (3). People with CKD often have abnormal blood lipid levels, high triglycerides (TG), low HDL cholesterol, and altered LDL particles, which contribute to atherosclerosis (4). They also have chronic inflammation [with elevated cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)] and increased oxidative stress (with increased reactive oxygen species and reduced antioxidant defenses), which impair blood vessel function, worsen kidney damage, and harm overall health (5). Many CKD patients also experience sleep disturbances such as insomnia and poor sleep quality, which further harm their health and quality of life (6).

Melatonin (MLT) is a hormone secreted by the pineal gland that helps regulate the circadian rhythm and the sleep–wake cycle. In addition to helping regulate sleep, melatonin also functions as an antioxidant, has anti-inflammatory effects, and offers protective benefits for the heart (7, 8). Because of these qualities, MLT shows potential for treating several problems linked to CKD (9).

Some studies suggest that MLT supplements might help improve sleep quality and support metabolic health in people with CKD (10). For instance, MLT could affect blood lipid and glucose levels (11). However, the findings are inconsistent and not conclusive (12–16), partly because of variations in study methods, doses, treatment lengths, and patient differences. So, a thorough systematic review and meta-analysis are necessary to compile all the existing data and better understand how melatonin might play a role in managing CKD.

Despite numerous clinical trials of MLT in CKD, there remains no consensus on its effectiveness. Without a comprehensive review of the evidence, clinicians lack clear guidance. This meta-analysis aims to systematically synthesize evidence from randomized controlled trials (RCTs) and observational studies to evaluate the effects of MLT supplementation on metabolic factors (e.g., blood lipids, glycemic, inflammatory markers, and oxidative stress markers) and sleep quality in patients with CKD. The goal is to clarify the potential benefits of melatonin for this high-risk group and to guide future research and clinical practice.

Methods

This systematic review was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines (17).

Search strategy

A systematic literature searches of online databases, including Scopus, the Cochrane Library, PubMed, Web of Science, and Embase, was conducted through May 30, 2025, with no restrictions on geographic area, publication date, or language. RCTs evaluating the effects of MLT on patients with CKD were managed using EndNote. The search terms used in this query include the following combinations (Supplementary Table 1). To ensure a comprehensive search, a back- and front-reference check was conducted on the identified articles to identify any studies that might have been overlooked in the primary systematic search.

Inclusion and exclusion criteria

The inclusion criteria were: (1) studies, (2) reported results on lipid profiles, oxidative stress (MDA), inflammatory markers (CRP), (3) and sleep quality (PSQI) (4) the intervention group received an MLT supplement, while the control group received a placebo or no treatment in patients diagnosed with CKD. The exclusion criteria were: (1) meta-analyses, comments, letters, reviews, case reports, animal studies, in vivo and in vitro, (2) insufficient reporting of data, and (3) co-supplementation of data. We have excluded observational, case–control, cohort, cross-sectional, retrospective, and environmental studies. Studies without our variables of interest, laboratory studies, studies with insufficient data, and those in which CD was not administered orally were also excluded.

Study selection and data extraction

Data selection and extraction were conducted independently by two researchers, using inclusion and exclusion criteria, based on a full-text review of the articles. Initially, the titles and abstracts of all the articles we found were reviewed to find studies that might be related. Those that seemed relevant were then chosen for a detailed full-text review. During this detailed review, two reviewers independently examined each study to decide whether it should be included. Any conflicting decisions by the evaluators to include a study were resolved by consensus. The following data have been extracted from the pooled data: (1) reference (year of publication and name of first author); (2) country of study; (3) characteristics of the population (age, sex), and size of the sample. (4) the characteristics of the intervention, the dose of the adjuvant, placebo, or control, and the type of RCT (parallel, or crossover).

Quality assessment and GRADE approach

The methodological quality of the RCTs was evaluated by two independent authors using the Cochrane Risk of Bias (ROB 2) tool (18), who assessed randomization, allocation, blinding, incomplete data, and selective reporting; a third author resolved the inconsistencies.

The GRADE methodology was used to evaluate the overall quality of the evidence (19). This method considers factors such as risk of bias, accuracy, inconsistency, and publication bias to assess the reliability of the evidence.

Statistical analysis

Synthesis data consisted of mean changes and corresponding SDs, with the DerSimonian-Laird random-effects model implemented in Stata 17.0 (Stata Corp., College Station, Texas, United States). The effect estimates were presented as weighted average differences (WMDs) with 95% confidence intervals (CIs). Crossover trials were analyzed using end-of-period data, and in multi-arm studies the control group was split or a single intervention arm was included to avoid double-counting, following Cochrane Handbook guidance. Inter-study heterogeneity was assessed using the Cochran Q test and the I² statistic; p-values < 0.1 or I² > 50% indicated significant inter-study heterogeneity. Sensitivity analyses were performed to investigate the robustness of the findings. In addition, subgroup analyses were conducted to identify sources of differences in dose, age, and treatment duration. Possible evidence of publication bias was statistically assessed using Begg’s test across the RCTs (20).

Results

Literature screening and study characteristics

Figure 1 shows the process of selecting studies. In total, 1,050 articles were subject to the first review. After removing duplicates, the authors reviewed the titles and abstracts of the 874remaining datasets, excluding 750 irrelevant links. In the next step, 14 documents were excluded following a full-text examination. Finally, 10 eligible RCTs with 12 arms were included in this meta-analysis. As shown in Table 1, trials were conducted between 2013 (12) and 2025 (15), with sample sizes ranging from 13 to 102 participants, treatment durations of 4 to 24 weeks, and MLT supplement doses of 3 to 10 mg/day. The trials were conducted in different countries, including Iran, Africa, and Iraq.

Figure 1

Figure 1. PRISMA flow diagram of study selection.

Table 1

Table 1. Characteristics of included studies in the meta-analysis.

Risk of bias and certainty of evidence

Table 2 presents the methodological quality assessment of the trials using the RoB2 tool, reflecting the authors’ judgments across the risk-of-bias domains. The certainty of evidence was high for HDL-C and moderate for all other outcomes, including TC, TG, LDL-C, MDA, CRP, and PSQI (Supplementary Table 2).

Table 2

Table 2. Quality assessment.

Effects of MLT on lipid profile

The results of our analysis showed that MLT did not significantly affect TC (WMD = −4.98, 95% CI: −11.28, 12.81, p = 0.122; I² = 0.0%, p = 0.767; Figure 2A), TG (WMD = −16.95, 95% CI: 38.68, 4.77, p = 0.126; I² = 69.1%, p = 0.021; Figure 2B), or LDL-C (WMD = −4.95, 95% CI: −12.11, 2.21, p = 0.175; I² = 24.9%, p = 0.264; Figure 2C) compared with placebo. In addition, meta-analysis demonstrated that MLT supplementation significantly increased HDL-C (WMD = 1.87, 95% CI: 0.24, 3.50, p = 0.025; I² = 38.9, p = 0.179; Figure 2D). Age, dosage, and intervention duration were identified as sources of heterogeneity. However, subgroup analyses indicated that the results remained statistically no significant (Table 2).

Figure 2

Figure 2. Forest plots of the effects of melatonin (MLT) on (A) TC, (B) TG, (C) LDL-C, and (D) HDL-C.

Effects of MLT on oxidative stress and inflammation

Meta-analysis demonstrated that MLT supplementation significantly reduced MDA (WMD = −1.28, 95% CI: −2.50, −0.06, p = 0.039; I² = 93.4, p < 0.001; Figure 3A), whereas CRP was not significantly affected (WMD = −0.61, 95% CI: −1.58, 0.37, p = 0.224; I² = 69.8, p = 0.003; Figure 3B) compared to placebo. Subgroup analysis showed that, compared with placebo, MLT supplementation was associated with a more robust decrease in MDA levels at doses < 5 mg/day and in participants <60 years old (Table 3).

Figure 3

Figure 3. Forest plots of the effects of melatonin (MLT) on (A) MDA and (B) CRP.

Table 3

Table 3. Subgroup analysis based on duration, dose, and age.

Effects of MLT on sleep quality

The result of combining the data showed a significant effect of the MLT supplementation on Pittsburgh Sleep Quality Index (PSQI) (WMD = -3.75, 95% CI: −6.92, −0.57, p = 0.021; I² = 94.2, p < 0.001; Figure 4).

Figure 4

Figure 4. Forest plot of the effect of melatonin (MLT) on sleep quality (PSQI).

Sensitivity analysis and publication bias

Sensitivity analysis showed no significant effect on the TG, TC, and LDL-C and confirmed the robustness of these results. However, for the HDL-C (12, 16), MDA (21, 22), and PSQI (23), the pooled effects changed from statistically significant to non-significant after the exclusion of individual studies (Supplementary Figures 1–7). According to Begg’s tests, there was no evidence of significant publication bias for TG (p = 0.999), TC (p = 0.734), LDL-C (p = 0.602), HDL-C (p = 0.174), CRP (p = 0.764), MDA (p = 0.999), and PSQI (p = 0.999).

Discussion

This meta-analysis of RCTs involving patients with CKD shows that MLT supplementation offers some small benefits for certain outcomes. However, many lipid and inflammatory markers did not show significant changes. Notably, MLT was linked to an increase in HDL-C, a decrease in MDA, and better sleep quality. On the other hand, levels of TC, LDL-C, TG, and CRP did not significantly alter. In the following discussion, we examine what these findings mean clinically, explore possible reasons for differences across studies, and consider what this means for future research.

Effects on lipid profiles

MLT supplementation led to a small but statistically significant increase in HDL-C (mean difference approximately +1.9 mg/dL) (24). HDL particles exert anti-atherogenic effects through reverse cholesterol transport as well as antioxidant and anti-inflammatory mechanisms, making this finding potentially relevant in CKD, a population in which low HDL-C levels are common (25). The observed increase in HDL-C was modest in scale. Importantly, medications aimed at raising HDL-C levels have generally not led to a decrease in cardiovascular events (26). This suggests that while melatonin may slightly raise HDL-C, the clinical significance of this change is uncertain. An increase of about 2 mg/dL alone is unlikely to provide meaningful cardiovascular benefit unless it is accompanied by improvements in HDL function or other positive changes in lipid profiles. MLT supplementation did not significantly affect TC, LDL-C, or TG levels in the pooled analysis. This result aligns with several individual studies that found no significant changes in LDL-C or triglyceride levels following short-term supplementation (27). The lack of effect could be due to methodological issues, such as small sample sizes, brief intervention periods, or interference from other lipid-lowering treatments, since many CKD patients are on medications like statins that strongly affect lipid profiles.

It is also conceivable that higher doses or longer durations of MLT treatment may be necessary to observe lipid-modulating effects beyond those investigated in the current studies (28). Considering the considerable variability among the trials, including differences in CKD stages, dialysis status, baseline lipid levels, and concomitant medications, these null results should be interpreted with caution. They do not rule out potential benefits for certain CKD subpopulations, underscoring the importance of conducting larger, well-designed studies with prolonged follow-up periods.

Effects on oxidative stress and inflammation

Inflammatory outcomes in the present meta-analysis should be interpreted in the context of the limited scope of the included studies. Only CRP was consistently reported across the eligible RCTs, which restricted our ability to evaluate the broader anti-inflammatory effects of MLT. MLT supplementation markedly decreased MDA levels, with a weighted mean difference of approximately −1.3 units and a p-value near 0.04. MDA is a recognized biomarker for lipid peroxidation and oxidative stress. A reduction in MDA levels indicates that melatonin may exert antioxidant effects in patients with CKD, consistent with its established role as a free-radical scavenger (15). Although theoretically, lowering MDA could safeguard cells from oxidative damage, the magnitude of change observed was modest, similar to the change in HDL-C, and it remains uncertain whether this slight decrease translates into significant clinical benefits.

MLT’s effects on MDA may also be context-dependent. In other experimental models, such as trauma, the timing of administration influenced whether MDA levels increased or decreased (29). In the trials included in this meta-analysis, no reduction in CRP, a general marker of systemic inflammation, was observed. This suggests that short-term MLT supplementation does not significantly affect inflammatory status in CKD patients. Likewise, high-sensitivity CRP (hs-CRP) levels remained stable. Due to the complex and multifactorial nature of CKD-related inflammation, more effective or longer-lasting interventions are generally needed to achieve noticeable decreases. The absence of a CRP-lowering effect indicates that MLT’s anti-inflammatory actions, such as inhibiting NF-κB, were not enough to alter circulating inflammatory markers in these studies (30). Overall, our findings suggest that melatonin more reliably reduces oxidative stress, as shown by MDA levels, than it does reduce systemic inflammation contexts.

Effects on sleep quality

Melatonin supplementation produced a meaningful improvement in sleep, as reflected by pooled Pittsburgh Sleep Quality Index (PSQI) scores. Specifically, global PSQI scores decreased by approximately 3.8 points, indicating improved subjective sleep quality. This aligns with melatonin’s established role as a circadian regulator: exogenous melatonin promotes sleep onset and reduces sleep latency in humans.

Patients with CKD often have disrupted melatonin rhythms, partly because their bodies cannot clear it properly (31, 32). This disruption can lead to difficulties falling asleep and poor sleep quality. Research has shown that in dialysis patients, taking melatonin supplements can improve how long and how well they sleep. Better sleep can enhance overall quality of life and may also have positive effects on heart and metabolic health.

Clinical significance of changes

While the observed changes in HDL-C and MDA were statistically significant, their small size means we should be cautious in interpreting these results. A roughly 2 mg/dL increase in HDL-C is much less than what is typically seen with standard lipid-lowering therapies, and simply raising HDL levels has not consistently improved heart health outcomes. Similarly, a reduction of approximately 1.3 units in MDA suggests decreased lipid peroxidation, but it is unclear if this leads to significant reductions in tissue oxidative damage. While MDA is a widely used marker for oxidative stress, it does not directly induce disease.

In simpler terms, our findings indicate initial biochemical effects, such as a slight rise in HDL and a reduction in MDA, but these alone may not translate into significant clinical benefits. This underscores the distinction between statistical significance and genuine health improvements. To determine whether these minor biomarker shifts impact patient health, larger, more rigorous studies that examine real health outcomes like heart attacks or kidney disease progression are essential.

Limitations and heterogeneity

Our findings should be approached with caution because of several limitations. Firstly, the trials involved different patient groups, some with dialysis and others without, varied MLT doses ranging from 3 to 10 mg per day, and different durations from 4 to 24 weeks, which created clinical and statistical differences. Secondly, only 10 RCTs with 12 study arms were included, most having small sample sizes of fewer than 50 participants. This limits the accuracy of the results and reduces the power of subgroup analyses. Sensitivity tests indicated that removing individual studies might cause some significant findings, such as effects on HDL-C, MDA, and PSQI, to disappear. Thirdly, the follow-up periods were generally short, making it impossible to evaluate long-term outcomes like cardiovascular events or the progression of CKD. Lastly, biases could still be present, including unreported small negative studies and the absence of individual patient data to adjust for baseline differences like statin use or CKD severity.

Recommendations for future research

To fill current gaps in research, future studies should focus on conducting adequately powered trials to confirm these results and assess clinical outcomes such as cardiovascular events, progression of CKD, and mortality, in addition to biochemical markers. It’s also worth investigating whether varying doses or the timing of administration, like evening versus morning, can enhance lipid profiles, antioxidant effects, or sleep quality. Evaluating HDL particle function, including cholesterol efflux and anti-inflammatory capacity, along with a broader range of oxidative stress markers, will help us understand the full antioxidant potential of MLT. Studies should be tailored specifically for dialysis and non-dialysis patients, as well as for older or more advanced CKD groups, to better identify who benefits the most. It’s also important to use the same methods consistently to measure lipid levels, oxidative stress markers, and sleep quality, like the Pittsburgh Sleep Quality Index, to minimize variability and make it easier to compare results across different studies.

Conclusion

We concluded that although MLT supplements increase HDL-C levels, they reduce oxidative stress, as indicated by MDA, and improve sleep quality in CKD patients. However, they did not affect other lipid or inflammatory markers. The clinical significance of these modest benefits is uncertain due to variability across studies and the small sample sizes. These findings support the need for larger, carefully designed studies to assess whether melatonin can benefit CKD patients.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Author contributions

QA: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing. ZG: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. MM: Conceptualization, Methodology, Project administration, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing. AsK: Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing. HA: Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing. NK: Funding acquisition, Software, Supervision, Writing – original draft, Writing – review & editing. DS: Conceptualization, Methodology, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing. AzK: Conceptualization, Data curation, Formal analysis, Software, Supervision, Validation, Writing – original draft, Writing – review & editing. WT: Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Writing – original draft, Writing – review & editing. MA: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing. MJ: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. AH: Formal analysis, Investigation, Methodology, Project administration, Software, Writing – original draft, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2026.1772877/full#supplementary-material

References

1. Cockwell, P, and Fisher, L-A. The global burden of chronic kidney disease. Lancet. (2020) 395:662–4. doi: 10.1016/S0140-6736(19)32977-0

Crossref Full Text | Google Scholar

2. Hall, ME, Do Carmo, JM, Da Silva, AA, Juncos, LA, Wang, Z, and Hall, JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renov Dis. (2014) 7:75–88. doi: 10.2147/IJNRD.S39739

Crossref Full Text | Google Scholar

3. Podkowińska, A, and Formanowicz, D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease. Antioxidants. (2020) 9:752. doi: 10.3390/antiox9080752

Crossref Full Text | Google Scholar

4. Keane, WF, Tomassini, JE, and Neff, DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb. (2013) 20:123–33.

PubMed Abstract | Google Scholar

5. Ranneh, Y, and Fadel, A. Crosstalk between reactive oxygen species and pro-inflammatory markers in developing various chronic diseases: a review. Appl Biol Chem. (2017) 60:327–38. doi: 10.1007/s13765-017-0285-9

Crossref Full Text | Google Scholar

6. Roumelioti, ME, Argyropoulos, CP, and Unruh, ML. Sleep disorders in patients with CKD and ESRD In: D Cukor, SD Cohen, and PL Kimmel, editors. Psychosocial aspects of chronic kidney disease. Amsterdam, Netherlands: Elsevier (2021). 183–212.

Google Scholar

7. Megha, K, Arathi, A, Shikha, S, Alka, R, Ramya, P, and Mohanan, PV. Significance of melatonin in the regulation of circadian rhythms and disease management. Mol Neurobiol. (2024) 61:5541–71. doi: 10.1007/s12035-024-03915-0,

PubMed Abstract | Crossref Full Text | Google Scholar

8. Samanta, S. Physiological and pharmacological perspectives of melatonin. Arch Physiol Biochem. (2022) 128:1346–67. doi: 10.1080/13813455.2020.1770799,

PubMed Abstract | Crossref Full Text | Google Scholar

9. Cupisti, A, Brunori, G, di Iorio, BR, D'Alessandro, C, Pasticci, F, Cosola, C, et al. Nutritional treatment of advanced CKD: twenty consensus statements. J Nephrol. (2018) 31:457–73. doi: 10.1007/s40620-018-0497-z,

PubMed Abstract | Crossref Full Text | Google Scholar

10. Sadeghi, S, Hakemi, MS, Pourrezagholie, F, Naeini, F, Imani, H, and Mohammadi, H. Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial. Trials. (2024) 25:757. doi: 10.1186/s13063-024-08584-x,

PubMed Abstract | Crossref Full Text | Google Scholar

11. Mohammadi-Sartang, M, Ghorbani, M, and Mazloom, Z. Effects of melatonin supplementation on blood lipid concentrations: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr. (2018) 37:1943–54. doi: 10.1016/j.clnu.2017.11.003,

PubMed Abstract | Crossref Full Text | Google Scholar

12. Edalat-Nejad, M, Haqhverdi, F, Hossein-Tabar, T, and Ahmadian, M. Melatonin improves sleep quality in hemodialysis patients. Indian J Nephrol. (2013) 23:264–9. doi: 10.4103/0971-4065.114488,

PubMed Abstract | Crossref Full Text | Google Scholar

13. Marzieh, SH, Jafari, H, Shorofi, SA, Setareh, J, Moosazadeh, M, Espahbodi, F, et al. The effect of melatonin on sleep quality and cognitive function of individuals undergoing hemodialysis. Sleep Med. (2023) 111:105–10. doi: 10.1016/j.sleep.2023.09.011,

PubMed Abstract | Crossref Full Text | Google Scholar

14. Marzougui, H, Turki, M, Ben Dhia, I, Maaloul, R, Chaker, H, Makhlouf, R, et al. Melatonin intake before intradialytic exercise reverses oxidative stress and improves antioxidant status in hemodialysis patients. Int J Artif Organs. (2023) 46:264–73. doi: 10.1177/03913988231165324,

PubMed Abstract | Crossref Full Text | Google Scholar

15. Sadeghi, S, Nassiri, A, Hakemi, MS, Hosseini, F, Pourrezagholie, F, Naeini, F, et al. Effects of melatonin supplementation on oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: a double-blind, randomized controlled trial. BMC Nutr. (2025) 11:34. doi: 10.1186/s40795-025-01026-0,

PubMed Abstract | Crossref Full Text | Google Scholar

16. Zahed, N, Pouyamehr, M, and Taherkhani, A. Effect of melatonin on C-reactive protein and lipid profile of hemodialysis patients. J Renal Injury Prevent. (2021):11. doi: 10.34172/jrip.2022.28848

Crossref Full Text | Google Scholar

17. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. (2021) 88:105906. doi: 10.1136/bmj.n71,

PubMed Abstract | Crossref Full Text | Google Scholar

18. Minozzi, S, Cinquini, M, Gianola, S, Gonzalez-Lorenzo, M, and Banzi, R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. (2020) 126:37–44. doi: 10.1016/j.jclinepi.2020.06.015,

PubMed Abstract | Crossref Full Text | Google Scholar

19. Atkins, D, Best, D, Briss, PA, Eccles, M, Falck-Ytter, Y, Flottorp, S, et al. Grading quality of evidence and strength of recommendations. BMJ. (2004) 328:1490. doi: 10.1136/bmj.328.7454.1490,

PubMed Abstract | Crossref Full Text | Google Scholar

20. Lin, L, Chu, H, Murad, MH, Hong, C, Qu, Z, Cole, SR, et al. Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med. (2018) 33:1260–7. doi: 10.1007/s11606-018-4425-7,

PubMed Abstract | Crossref Full Text | Google Scholar

21. Marzougui, H, Hammouda, O, Ben Dhia, I, Maaloul, R, Agrebi, I, Chaker, H, et al. Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients. Int Urol Nephrol. (2021) 53:553–62. doi: 10.1007/s11255-020-02643-3,

PubMed Abstract | Crossref Full Text | Google Scholar

22. Al Lami, HCA. Melatonin improves lipid profile and ameliorates lipid peroxidation in patients with chronic kidney disease. Al Mustansiriyah. J Pharm Sci. (2018) 18:38–45. doi: 10.32947/ajps.18.01.0360

Crossref Full Text | Google Scholar

23. Ostadmohammadi, V, Soleimani, A, Bahmani, F, Aghadavod, E, Ramezani, R, Reiter, RJ, et al. The effects of melatonin supplementation on parameters of mental health, Glycemic control, markers of cardiometabolic risk, and oxidative stress in diabetic Hemodialysis patients: a randomized, double-blind. Placebo Controll Trial J Ren Nutr. (2020) 30:242–50. doi: 10.1053/j.jrn.2019.08.003,

PubMed Abstract | Crossref Full Text | Google Scholar

24. Koziróg, M, Poliwczak, AR, Duchnowicz, P, Koter-Michalak, M, Sikora, J, and Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. (2011) 50:261–6. doi: 10.1111/j.1600-079X.2010.00835.x,

PubMed Abstract | Crossref Full Text | Google Scholar

25. Rysz-Górzyńska, M, and Banach, M. Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Arch Med Sci. (2016) 12:844–9. doi: 10.5114/aoms.2016.60971,

PubMed Abstract | Crossref Full Text | Google Scholar

26. Ali, KM, Wonnerth, A, Huber, K, and Wojta, J. Cardiovascular disease risk reduction by raising HDL cholesterol–current therapies and future opportunities. Br J Pharmacol. (2012) 167:1177–94. doi: 10.1111/j.1476-5381.2012.02081.x,

PubMed Abstract | Crossref Full Text | Google Scholar

27. Loloei, S, Sepidarkish, M, Heydarian, A, Tahvilian, N, Khazdouz, M, Heshmati, J, et al. The effect of melatonin supplementation on lipid profile and anthropometric indices: a systematic review and meta-analysis of clinical trials. Diabetes Metab Syndr Clin Res Rev. (2019) 13:1901–10. doi: 10.1016/j.dsx.2019.04.043,

PubMed Abstract | Crossref Full Text | Google Scholar

28. Santos-Ledo, A, Luxán-Delgado, B, Caballero, B, Potes, Y, Rodríguez-González, S, Boga, JA, et al. Melatonin ameliorates autophagy impairment in a metabolic syndrome model. Antioxidants. (2021) 10:796. doi: 10.3390/antiox10050796

Crossref Full Text | Google Scholar

29. Joo, SS, and Yoo, Y-M. Protective effect of melatonin against bisphenol a toxicity. Int J Mol Sci. (2025) 26:7526. doi: 10.3390/ijms26157526

Crossref Full Text | Google Scholar

30. Unnikrishnan, D, Jun, J, and Polotsky, V. Inflammation in sleep apnea: an update. Rev Endocr Metab Disord. (2015) 16:25–34. doi: 10.1007/s11154-014-9304-x,

PubMed Abstract | Crossref Full Text | Google Scholar

31. Fatemeh, G, Sajjad, M, Niloufar, R, Neda, S, Leila, S, and Khadijeh, M. Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. J Neurol. (2022) 269:205–16. doi: 10.1007/s00415-020-10381-w,

PubMed Abstract | Crossref Full Text | Google Scholar

32. Mei, M, Zhou, Q, Gu, W, Li, F, Yang, R, Lei, H, et al. Dietary supplement interventions and sleep quality improvement: a systematic review and Meta-analysis. Nutrients. (2025) 17:3952. doi: 10.3390/nu17243952

Crossref Full Text | Google Scholar

33. Marzougui, H, Ben Dhia, I, Mezghani, I, Maaloul, R, Toumi, S, Kammoun, K, et al. The synergistic effect of intradialytic concurrent training and melatonin supplementation on oxidative stress and inflammation in Hemodialysis patients: a double-blind randomized controlled trial. Antioxidants. (2024) 13:1290. doi: 10.3390/antiox13111290

Crossref Full Text | Google Scholar

34. Talari, HR, Tabatabaei, SMH, Soleimani, A, Sayyah, M, and Bozorgi, M. The effects of melatonin administration on carotid intima-media thickness and pulse wave velocity in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. Clin Nutr ESPEN. (2022) 48:82–6. doi: 10.1016/j.clnesp.2022.01.002,

PubMed Abstract | Crossref Full Text | Google Scholar